NASHVILLE, Tenn. / Oct 26, 2023 / Business Wire / HCA Healthcare, Inc. (NYSE:HCA) today announced the Company will host its 2023 Investor Day with analysts and institutional investors on Thursday, November 9, 2023, beginning at 8:00 a.m. CT.
A team of HCA Healthcare leaders will offer perspectives on the Company’s financial performance, operations, and strategies to drive growth and create value. In conjunction with Investor Day, the Company plans to provide early perspectives on the outlook for 2024 and longer-term financial targets.
The Company will stream the presentations and the management question and answer portion of Investor Day and will make conference materials available on its Investor Relations page (https://investor.hcahealthcare.com/events-and-presentations/default.aspx) at approximately 6:30 a.m. CT on November 9, 2023. Investor Day is expected to conclude at approximately 3:45 p.m. CT. A replay will be available on the Company website beginning Friday, November 10, 2023, at 4:00 p.m. CT.
About the Company
As of September 30, 2023, HCA Healthcare operated 183 hospitals and approximately 2,300 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom.
| Last Trade: | US$296.70 |
| Daily Change: | -1.05 -0.35 |
| Daily Volume: | 1,218,501 |
| Market Cap: | US$75.150B |
October 25, 2024 October 17, 2024 July 23, 2024 April 26, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
